Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice

被引:44
|
作者
Bolivar, VJ
Manley, K
Messer, A
机构
[1] New York State Dept Hlth, Wadsworth Ctr Labs & Res, David Axelrod Inst, Albany, NY 12201 USA
[2] SUNY Albany, Dept Biomed Sci, Albany, NY USA
关键词
D O I
10.1037/0735-7044.117.6.1233
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The Huntington's disease R6/2 transgenic mouse model, containing exon 1 of the human huntingtin gene with a greatly increased CAG repeat length, shows multiple effects of the altered polyglutamine in the resultant protein. The authors report that exploratory and fear conditioning behavioral changes appear well before the onset of obvious pathology. The first differences in exploratory and fear conditioning behavior emerge by 4 and 5 weeks of age, respectively. These behaviors correlate with the earliest neurochemical and molecular changes previously reported and provide insight into functional mechanisms by which cellular and subcellular disease changes may mediate neurological symptoms. These studies provide behavioral protocols suitable for high-throughput screening of therapeutic agents.
引用
收藏
页码:1233 / 1242
页数:10
相关论文
共 50 条
  • [41] LAQUINIMOD IN THE R6/2 MOUSE MODEL OF HUNTINGTON'S DISEASE
    Ellrichmann, Gisa
    Blusch, Alina
    Fatoba, Oluwaseun
    Brunner, Janine
    Pitarokoili, Kalliopi
    Hayardeny, Liat
    Saft, Carsten
    Gold, Ralf
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A92 - A92
  • [42] Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease:: behavioral testing and impact of diabetes mellitus
    Lüesse, HG
    Schiefer, J
    Spruenken, A
    Puls, C
    Block, F
    Kosinski, CM
    BEHAVIOURAL BRAIN RESEARCH, 2001, 126 (1-2) : 185 - 195
  • [43] Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients
    Sathasivam, K
    Woodman, B
    Mahal, A
    Bertaux, F
    Wanker, EE
    Shima, DT
    Bates, GP
    HUMAN MOLECULAR GENETICS, 2001, 10 (21) : 2425 - 2435
  • [44] Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex
    Walker, Adam G.
    Ummel, Jason R.
    Rebec, George V.
    NEUROBIOLOGY OF DISEASE, 2011, 43 (02) : 379 - 387
  • [45] Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease
    Acevedo-Torres, Karina
    Berrios, Lexsy
    Rosario, Nydia
    Dufault, Vanessa
    Skatchkov, Serguei
    Eaton, Misty J.
    Torres-Ramos, Carlos A.
    Ayala-Torres, Sylvette
    DNA REPAIR, 2009, 8 (01) : 126 - 136
  • [46] Right Ventricular Dysfunction in the R6/2 Transgenic Mouse Model of Huntington's Disease is Unmasked by Dobutamine
    Buonincontri, Guido
    Wood, Nigel I.
    Puttick, Simon G.
    Ward, Alex O.
    Carpenter, T. Adrian
    Sawiak, Stephen J.
    Morton, A. Jennifer
    JOURNAL OF HUNTINGTONS DISEASE, 2014, 3 (01) : 25 - 32
  • [47] CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse
    Dragatsis, I.
    Goldowitz, D.
    Del Mar, N.
    Deng, Y. P.
    Meade, C. A.
    Liu, Li
    Sun, Z.
    Dietrich, P.
    Yue, J.
    Reiner, A.
    NEUROBIOLOGY OF DISEASE, 2009, 33 (03) : 315 - 330
  • [48] Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease
    S Zhu
    Y Zhang
    G Bai
    H Li
    Cell Death & Disease, 2011, 2 : e115 - e115
  • [49] A Comprehensive Description of the Progressive Pathology Exhibited by the R6/2 Transgenic Mouse Model of Huntington's Disease
    Rattray, I.
    Gale, R.
    Smith, E.
    Matsumoto, K.
    Bates, G.
    Modo, M.
    CELL TRANSPLANTATION, 2012, 21 (04) : 788 - 788
  • [50] Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease
    Josefsen, K.
    Nielsen, M. D.
    Jorgensen, K. H.
    Bock, T.
    Norremolle, A.
    Sorensen, S. A.
    Naver, B.
    Hasholt, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2008, 20 (02) : 165 - 172